Innovative Approaches for Diagnosing NAFLD and NASH: Moving Beyond Liver Biopsy

Medical

Non-Alcoholic Fatty Liver Disease (NAFLD) is a prevalent and escalating liver condition linked to the global rise in obesity, type 2 diabetes, and metabolic syndrome. NAFLD encompasses a spectrum of liver disorders, ranging from Non-Alcoholic Fatty Liver (NAFL), characterized by liver fat accumulation without significant inflammation, to the more severe Non-Alcoholic Steatohepatitis (NASH), which includes inflammation and liver cell injury, potentially leading to fibrosis and cirrhosis. Accurate differentiation between NAFL and NASH is crucial for prognosis and treatment. Various diagnostic approaches have been explored, including blood and serum tests assessing steatosis, steatohepatitis, and fibrosis. Imaging techniques such as ultrasound, elastography, and Magnetic Resonance Imaging (MRI) offer non-invasive alternatives, while genetic tests reveal important risk factors. Notably, emerging research highlights the role of exosomes, adipose tissue, and gut microbiota in NAFLD pathogenesis. Despite advancements, NAFLD diagnosis remains a complex challenge, requiring a combination of clinical, biochemical, imaging, and genetic approaches. Identifying high-risk populations and understanding the interplay of contributing factors is essential for early intervention and effective management of this growing public health concern.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.